home / stock / repl / repl articles

REPL Articles, Replimune Group Inc.

Stock Information
Company Name: Replimune Group Inc.
Stock Symbol: REPL
Market: NASDAQ
Menu
REPL REPL Quote REPL Short REPL News REPL Articles REPL Message Board
Get REPL Alerts

News, Short Squeeze, Breakout and More Instantly...
Replimune Announces Appointment of Sushil Patel to CEO and Executive Leadership Transitions | Benzinga

Philip Astley-Sparke to transition from current role of CEO to Executive Chairman Planned leadership changes position the Company for commercializ...
Replimune to Present at Three Upcoming Investor Conferences | Benzinga

WOBURN, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the dev...

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference | Benzinga

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the deve...

Crude Oil Moves Lower; AutoZone Profit Tops Views | Benzinga

U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 whi...
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session | Benzinga

Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. Daktronics posted quarterly ...

Dow Falls 100 Points; ISM Services PMI Increases In November | Benzinga

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 100 points on Tuesday. The Dow traded down 0.28% to 36,103...

US Stocks Down; JM Smucker Posts Upbeat Earnings | Benzinga

U.S. stocks traded lower this morning, with the Nasdaq Composite falling over 50 points on Tuesday. Following the market opening Tuesday, the Dow t...
What's Going On With Cancer-Focused Replimune Stock Today? | Benzinga

Replimune Group Inc (NASDAQ: REPL) announced results from the primary analysis of the CERPASS trial evaluating RP1 in combination with cemipli...

Replimune Announces Appointment of Emily Hill as Chief Financial Officer | Benzinga

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ:REPL), a clinical stage biotechnology company pioneering the dev...

Next 10